On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
HOME > INTERVIEW
INTERVIEW
-
Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
February 10, 2020
-
“Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician
January 28, 2020
-
Causes of NDMA Contamination Scandal Still under Investigation: NIHS Division of Drugs
January 27, 2020
-
Pharma Industry Watered Down Original Proposals for Pricing Overhaul, Corrections Necessary: Kenporen Director
September 12, 2019
-
As New Era Dawns, Eisai CEO Says Pharma Could Be True Winner of 4th Industrial Revolution
May 8, 2019
-
Nichi-Iko to Leverage Synergies of Integration with Elmed Eisai: Sales Head
April 22, 2019
-
I’ve Done Everything I Can in 11 Years, Says Outgoing PMDA Chief
March 28, 2019
-
With HIV Back in Hand, Gilead Heading into Second Phase in Japan Market: Pres. Hermans
March 26, 2019
-
JMA Exec Matsumoto: CEA Scheme Merely a Supplemental Tool to Drug Pricing System, Continued Discussions Necessary
March 7, 2019
-
Interview: Pfizer Japan Looks to Offer High Quality Biosimilars with Go-It-Alone Strategy
February 2, 2018
-
Taiyo Pharma Eyeing 10 Trillion Yen Japanese Market, Looking to Use In-House Technologies to Develop New Products: COO
January 10, 2018
-
Chordia President Confident in Success of “Synthetic Lethality” Drug; Negotiated Directly with Takeda to Establish Startup
December 7, 2017
-
Takeda Eager to Build Life Science Hub in Shonan, Offer Research Environment Akin to US East Coast: Exec Hirate
October 24, 2017
-
Me Pharma Sees Opportunities in Low-Cost Strategy, Could Carve Out New Biz Models: President
August 14, 2017
-
Centerpiece of FPMAJ’s Lobbying Push Will Be Price Maintenance Premium: Chairman
April 14, 2017
-
Scohia Wants to Make Its “Carve Out” a Success Model for Japan Makers: CEO
April 5, 2017
-
Chugai to Execute Area-Based Strategy Centering on General Reps: Marketing Chief
March 6, 2017
-
Daiichi Sankyo Espha Eyes 50 Billion Yen Sales in 2020 with AGs as Growth Engine
February 28, 2017
-
Takeda’s Japan Biz “Going in Good Direction” towards 1st Underlying Sales Rise in 5 Years: Iwasaki
February 24, 2017
-
CEO Weber Says Takeda’s Ongoing Transformation “Irreversible”: Full Interview
February 8, 2017
ページ
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…